Psychedelic therapy could provide a major breakthrough in the treatment of mental health disorders like depression, and now it's caught the attention of start-ups and venture capitalists.
Laurence Knight hears from one man whose life was transformed by a single dose of the drug psilocybin - the psychoactive ingredient in magic mushrooms - after he volunteered for a research project exploring whether it could cure depression. He also visits the research team at King's College London, who have just wrapped up the latest trials of the drug.
The trials are being sponsored by the healthcare start-up Compass Pathways, and its founder and chief executive George Goldsmith explains why he hopes to use them to bring this therapy to the general public. Plus Amanda Eilian of venture capitalists Able Partners describes how quickly attitudes in the investor community are changing.
Podden och tillhörande omslagsbild på den här sidan tillhör BBC World Service. Innehållet i podden är skapat av BBC World Service och inte av, eller tillsammans med, Poddtoppen.
